

# BORTEZOMIB

BRAND NAME VELCADE, BORTEZOM, BORTEZOMIB ACCORD, AFT, EVER PHARMA, DBL, JUNO, SANDOZ, TEVA

DRUG CLASS Cytotoxic antineoplastic, proteasome inhibitor

AVAILABILITY Powder vial contains 1 mg, 2.5 mg, 3 mg or 3.5 mg of bortezomib. Also contains mannitol.<sup>1</sup>  
Solution vial contains 2.5 mg/1 mL or 3.5 mg/1.4 mL of bortezomib. Also contains mannitol.<sup>1</sup>

Cytotoxic. Strict handling precautions are required.  
Bortezomib is an irritant.<sup>1,2</sup>  
**Not** for intrathecal administration – contraindicated, may be fatal.<sup>1</sup>  
Solution vials from different manufacturers have different overages, check carefully when switching brands to prepare intravenous injections.

pH 2–6.5<sup>1</sup>

PREPARATION **In a cytotoxic drug safety cabinet:**  
**For SUBCUT use:** reconstitute the powder vial with sodium chloride 0.9% to make a concentration of 2.5 mg/mL:<sup>1</sup>

Powder vial	Volume of sodium chloride 0.9% to make 2.5 mg/mL
2.5 mg	1 mL
3 mg	1.2 mL
3.5 mg	1.4 mL

The 2.5 mg/1 mL and 3.5 mg/1.4 mL solution presentations are suitable for subcutaneous injection.<sup>1</sup>

**For IV use:** reconstitute the powder vial with sodium chloride 0.9% to make a concentration of 1 mg/mL, or dilute the solution vial to 1 mg/mL:<sup>1</sup>

Powder vial	Volume of sodium chloride 0.9% to make 1 mg/mL
1 mg	1 mL
2.5 mg	2.5 mL
3 mg	3 mL
3.5 mg	3.5 mL

  

Solution vial	Volume of sodium chloride 0.9% to make 1 mg/mL
Accord 2.5 mg/1 mL	1.6 mL
Ever Pharma 2.5 mg/1 mL	1.8 mL
Accord 3.5 mg/1.4 mL	2.2 mL
Ever Pharma 3.5 mg/1.4 mL	2.4 mL

The solution is clear and colourless to light yellow.<sup>1</sup>

**STABILITY** Accord, AFT, Bortezom, DBL, Sandoz, Teva and Velcade powder vials: store below 25 °C. Protect from light.<sup>1</sup>  
Accord, Ever Pharma solution vials: store at 2 to 8 °C. Protect from light.<sup>1</sup>  
Reconstituted solution: stable for 8 hours at 25 °C or at 2 to 8 °C.<sup>1</sup> Longer stability information is available.<sup>1,3</sup>

**ADMINISTRATION**

**IM injection** Not recommended

**SUBCUT injection** Use a 2.5 mg/mL concentration, see PREPARATION.<sup>1</sup>

Inject into the thigh or abdomen. Rotate the site of injection.<sup>1</sup> If injection-site reactions occur, use a 1 mg/mL dilution or change to IV administration.<sup>1</sup>

**IV injection** Use a 1 mg/mL concentration, see PREPARATION.<sup>1</sup>

Inject over 3 to 5 seconds into a peripheral line or central venous access device.<sup>1</sup>

**IV infusion** Not recommended

**COMPATIBILITY** Sodium chloride 0.9%<sup>1</sup>

**INCOMPATIBILITY** No information

**SPECIAL NOTES** Low emetogenic risk.<sup>4</sup> Check your local guidelines for premedication requirements.  
Give doses of bortezomib at least 72 hours apart.<sup>1</sup>

**REFERENCES**

1. Product information. Available from [www.tga.gov.au](http://www.tga.gov.au). Accessed 13/10/2022.
2. Clinical resource: Extravasation Management [v4 2019]. eviQ [internet]. Sydney: Cancer Institute NSW. Available from [www.eviq.org.au](http://www.eviq.org.au). Accessed 29/03/2022.
3. McEvoy GK editor. Handbook on injectable drugs. 20th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2018.
4. Clinical resource: Prevention of antineoplastic induced nausea and vomiting [v5 May 2021]. eviQ [internet]. Sydney: Cancer Institute NSW. Available from [www.eviq.org.au](http://www.eviq.org.au). Accessed 29/03/2022.